PCSK9 as predictor for recurrent cardiovascular disease in familial hypercholesterolemia

被引：2

作者：

Reeskamp, Laurens F. ^{[1
]}

Tromp, Tycho R. ^{[1
]}

Hovingh, G. Kees ^{[1
]}

机构：

[1] Univ Amsterdam, Amsterdam UMC, Dept Vasc Med, Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands

来源：

EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY | 2021年 / 28卷 / 03期

关键词：

CALCIFICATION; STATINS; EVENTS; RISK;

D O I：

10.1177/2047487319886140

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：270 / 271

页数：2

共 50 条

[41] Proprotein convertase subtilisin kexin 9 (PCSK9) inhibitors to treat hypercholesterolemia: Effect on stroke risk [J].

Milionis, Haralampos ;

Barkas, Fotios ;

Ntaios, George ;

Papavasileiou, Vasileios ;

Vemmos, Kostantinos ;

Michel, Patrick ;

Elisaf, Moses .

EUROPEAN JOURNAL OF INTERNAL MEDICINE, 2016, 34 :54-57

[42] Beyond Statins and PCSK9 Inhibitors: Updates in Management of Familial and Refractory Hypercholesterolemias [J].

Fabiana Rached ;

Raul D. Santos .

Current Cardiology Reports, 2021, 23

[43] PCSK9 promotes arterial medial calcification [J].

Bressan, Alessandro ;

Donato, Maristella ;

Canzano, Paola ;

Camera, Marina ;

Poggio, Paolo ;

Garofalo, Mariangela ;

Panighel, Giovanni ;

Ruscica, Massimiliano ;

Baragetti, Andrea ;

Bollati, Valentina ;

Faggin, Elisabetta ;

Rattazzi, Marcello ;

Catapano, Alberico L. ;

Ferri, Nicola ;

Lupo, Maria Giovanna ;

Greco, Maria Francesca ;

De Martin, Sara .

ATHEROSCLEROSIS, 2022, 346 :86-97

[44] PCSK9 Association With Lipoprotein(a) [J].

Tavori, Hagai ;

Christian, Devon ;

Minnier, Jessica ;

Plubell, Deanna ;

Shapiro, Michael D. ;

Yeang, Calvin ;

Giunzioni, Ilaria ;

Croyal, Mikael ;

Duell, P. Barton ;

Lambert, Gilles ;

Tsimikas, Sotirios ;

Fazio, Sergio .

CIRCULATION RESEARCH, 2016, 119 (01) :29-+

[45] Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors, Reality or Dream in Managing Patients with Cardiovascular Disease [J].

Alkhalil, Mohammad .

CURRENT DRUG METABOLISM, 2019, 20 (01) :72-82

[46] Trends in PCSK9 Inhibitor Prescriptions before and after the Price Reduction in Patients with Atherosclerotic Cardiovascular Disease [J].

Smith, Alex ;

Johnson, Drew ;

Banks, Joshua ;

Keith, Scott W. ;

Karalis, Dean G. .

JOURNAL OF CLINICAL MEDICINE, 2021, 10 (17)

[47] Adoption of PCSK9 Inhibitors Among Patients With Atherosclerotic Disease [J].

Dayoub, Elias J. ;

Eberly, Lauren A. ;

Nathan, Ashwin S. ;

Khatana, Sameed Ahmed M. ;

Adusumalli, Srinath ;

Navar, Ann Marie ;

Giri, Jay ;

Groeneveld, Peter W. .

JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2021, 10 (09)

[48] Acute-Phase Plasma PCSK9 Levels and Recurrent Cardiovascular Events in a Chinese Acute Myocardial Infarction Cohort [J].

Gao, Yan ;

Qiu, Yan ;

Wu, Jihua ;

Diao, Wei ;

Zhang, Haibo ;

Wang, Siming ;

Du, Zhiqiang ;

Dong, Jun ;

Zhang, Mingqiang ;

Jiang, Lixin .

CARDIOLOGY, 2018, 141 (02) :88-97

[49] Eligibility, Clinical Outcomes, and Budget Impact of PCSK9 Inhibitor Adoption: The CANHEART PCSK9 Study [J].

Ko, Dennis T. ;

Khan, Anam M. ;

Kotrri, Gynter ;

Austin, Peter C. ;

Wijeysundera, Harindra C. ;

Koh, Maria ;

Chu, Anna ;

Jackevicius, Cynthia A. ;

Lawler, Patrick R. ;

Tu, Jack V. .

JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2018, 7 (21)

[50] Circulating PCSK9 Level and Risk of Cardiovascular Events and Death in Hemodialysis Patients [J].

Hwang, Hyeon Seok ;

Kim, Jin Sug ;

Kim, Yang Gyun ;

Lee, So-Young ;

Ahn, Shin Young ;

Lee, Hong Joo ;

Lee, Dong-Young ;

Lee, Sang Ho ;

Moon, Ju Young ;

Jeong, Kyung Hwan .

JOURNAL OF CLINICAL MEDICINE, 2020, 9 (01)

← 1 2 3 4 5 →